

# Kathrin U Jansen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/169448/publications.pdf>

Version: 2024-02-01

26  
papers

19,079  
citations

279701

23  
h-index

552653

26  
g-index

26  
all docs

26  
docs citations

26  
times ranked

26556  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. <i>New England Journal of Medicine</i> , 2022, 386, 35-46.	13.9	431
2	Achieving end-to-end success in the clinic: Pfizer's learnings on R&D productivity. <i>Drug Discovery Today</i> , 2022, 27, 697-704.	3.2	17
3	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, 41.	2.9	4
4	Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. <i>New England Journal of Medicine</i> , 2022, 386, 1615-1626.	13.9	78
5	Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	63
6	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. <i>Nature</i> , 2021, 592, 283-289.	13.7	494
7	Neutralizing Activity of BNT162b2-Elicited Serum. <i>New England Journal of Medicine</i> , 2021, 384, 1466-1468.	13.9	528
8	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. <i>Nature</i> , 2021, 596, 273-275.	13.7	318
9	BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. <i>New England Journal of Medicine</i> , 2021, 385, 472-474.	13.9	93
10	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 239-250.	13.9	709
11	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. <i>New England Journal of Medicine</i> , 2021, 385, 1627-1629.	13.9	346
12	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773.	13.9	1,090
13	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <i>New England Journal of Medicine</i> , 2020, 383, 2439-2450.	13.9	2,107
14	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2603-2615.	13.9	11,472
15	Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine. <i>Npj Vaccines</i> , 2020, 5, 8.	2.9	9
16	Turning the corner on therapeutic cancer vaccines. <i>Npj Vaccines</i> , 2019, 4, 7.	2.9	490
17	Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine. <i>MBio</i> , 2018, 9, .	1.8	53
18	Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. <i>Vaccine</i> , 2017, 35, 1530-1537.	1.7	29

#	ARTICLE	IF	CITATIONS
19	<i>Neisseria meningitidis</i> Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 216-223.	1.1	41
20	Meningococcal serogroup B vaccines: Estimating breadth of coverage. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 255-265.	1.4	48
21	A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. <i>New England Journal of Medicine</i> , 2017, 377, 2349-2362.	13.9	57
22	The Discovery and Development of a Novel Vaccine to Protect against <i>Neisseria meningitidis</i> Serogroup B Disease. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 5-13.	1.4	84
23	A Multi-country Evaluation of <i>Neisseria meningitidis</i> Serogroup B Factor H Binding Proteins and Implications for Vaccine Coverage in Different Age Groups. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 1096-1101.	1.1	36
24	Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 597-607.	4.6	120
25	Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. <i>Vaccine</i> , 2010, 28, 6086-6093.	1.7	182
26	Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B <i>Neisseria meningitidis</i> . <i>Journal of Infectious Diseases</i> , 2009, 200, 379-389.	1.9	180